Cancer, one of the primary threats to human health, has seen its treatment methods evolve continuously. In recent years, with the rise of immunotherapy, countless patients have found new hope.
By leveraging world-leading 980nm Pulsed Photobiomodulation (PBM) technology, Fotonmedix has pioneered a non-drug, non-invasive path for anti-cancer therapy. This approach uses “light” to precisely reshape the tumor immune microenvironment and awaken the body’s own anti-tumor immunity. The research findings were successfully published in iScience (a flagship journal under Cell Press). This milestone represents a breakthrough for China in the field of photo-immunotherapy, laying a solid scientific foundation for precise, non-invasive tumor treatment and opening a new global direction for oncology.
Authoritative Certification: Showcasing the Strength of “Intelligent Manufacturing in China”
As a core flagship journal of Cell Press, iScience represents the highest international academic standards in life sciences and cross-disciplinary medicine.
The publication of Fotonmedix’s research in iScience serves as high-level recognition from the international academic community for Fotonmedix’s medical photo-immunomodulation technology. It further solidifies the medical translation foundation of Fotonmedix in the field of High-Energy Laser Photobiomodulation (PBM), demonstrating China’s global leadership in laser medicine.
Scientific Essence: How Does 980nm Pulsed Light Precisely “Fight Cancer”?
The immunosuppressive state of the tumor microenvironment is a critical pain point that causes immunotherapy to fail. Fotonmedix’s 980nm Pulsed PBM technology moves beyond traditional treatment logic to achieve three core breakthroughs:
01. Precisely Awakening “Exhausted” Immune Cells
Within the tumor microenvironment, cytotoxic CD8⁺ T cells often fall into a state of immune exhaustion, losing their ability to fight. Research confirms that daily irradiation with 980nm pulsed light can effectively reverse this state:
Significantly down-regulates the expression of exhaustion markers (PD-1, TIM-3).
Simultaneously increases levels of Reactive Oxygen Species (ROS) and killing factors (Granzyme B).
This “reboots and empowers” exhausted immune guards, restoring their anti-cancer combat capabilities.
02. Localized Precision Reshaping, Avoiding “Systemic Side Effects”
Traditional chemotherapy and immunotherapy drugs are mostly systemic treatments, which often trigger systemic adverse reactions. In contrast, 980nm pulsed light offers physical advantages of high penetration and non-thermal effects:
It does not cause thermal damage to tissue or direct toxicity to healthy cells.
The immune remodeling effect is strictly confined to the irradiated area; only the tumor on the irradiated side is inhibited, while the contralateral side remains unaffected.
This allows for precise local immune activation, completely avoiding the systemic toxicity risks associated with traditional therapies.
03. Long-term Immune Memory to Prevent Tumor Recurrence
The study also found that in models where tumors completely regressed following 980nm PBM treatment, the body exhibited strong resistance when re-challenged with the same type of tumor cells. This indicates that pulsed light therapy can not only clear existing tumors but also build a long-term, sustained immune memory barrier within the body, providing a viable possibility for preventing cancer recurrence.
Experimental Evidence: This technology significantly inhibits early-stage tumor growth and forms a lasting immune memory even after treatment stops. This offers a brand-new combination strategy for treating solid tumors such as colorectal and lung cancer.
The Future is Here: Making Light a “Precision Blade” Against Cancer
From laboratory breakthroughs to clinical translation, Fotonmedix has always focused on “non-invasive, safe, and efficient” solutions, deeply cultivating photobiomodulation technology. This publication in a Cell sub-journal is both a milestone and a new starting point.
Moving forward, Fotonmedix will continue to delve into the frontiers of laser medicine, accelerating the implementation of top-tier academic achievements into accessible, high-end medical devices, and joining forces with industry partners to open a new era of photomedicine and photo-immunotherapy!
About Fotonmedix
Fotonmedix is an innovative manufacturer of high-energy laser medical equipment, specializing in the R&D and production of hospital-grade and home-use medical devices for minimally invasive surgery, dentistry, vascular surgery, urology, photodynamic therapy (PDT), orthopedics, rehabilitation, and medical aesthetics. The company’s self-developed high-energy lasers have been exported to major developed markets, including Germany, France, Switzerland, the USA, Israel, and Japan. By combining advanced high-energy laser technology with cutting-edge clinical research, Fotonmedix is dedicated to designing superior medical laser equipment and providing safe, comfortable, and effective health solutions to customers worldwide.
FotonMedix
